Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1003664

registered interest
date	09/11/2018
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Musicians: British Nationals Abroad
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Digital, Culture, Media and Sport, what assessment he has made of the effect of leaving the Digital Single Market on the royalties earned in EU countries by UK musicians.
tabling member constituency	Bury North
tabling member printed	James Frith
uin	189800
answer	answer is ministerial correction date of answer 14/11/2018 answer text <p>No such assessment has been made to date. This is because rights holders tend to use collective management organisation (CMOs) to collect and distribute royalties earned in other EU countries. UK and EU CMOs enter into reciprocal agreements with each other to do this. These are private commercial agreements between the parties which we would expect to continue after the UK has exited the Digital Single Market.</p> answering member constituency East Surrey answering member printed Mr Sam Gyimah question first answered 14/11/2018 18:00:14 answering member 3980 label Biography information for Mr Sam Gyimah
tabling member	4637 label Biography information for James Frith

1002604

registered interest
date	06/11/2018
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Driver and Vehicle Licensing Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, how much revenue the Driver and Vehicle Licensing Agency raised from selling personal data to third parties in the last financial year.
tabling member constituency	Linlithgow and East Falkirk
tabling member printed	Martyn Day
uin	188880
answer	answer is ministerial correction date of answer 12/11/2018 answer text <p>The Driver and Vehicle Licensing Agency (DVLA) neither promotes the release of personal data, nor does the DVLA seek to release personal data to generate a fee/revenue.</p><p> </p><p>DVLA responds, as required, to each request for vehicle and driver data and while DVLA is permitted to charge a fee for the release of information under the reasonable cause provisions, DVLA is not permitted to profit from the release. The fee set is to recover the related administrative costs and this means that it is the applicant and not the taxpayer that funds this activity.</p><p> </p><p>Total fees recognised by DVLA from charges for requests for vehicle and driver personal data for the most recent financial year available, is:</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2017-18</p></td></tr><tr><td><p>Account</p></td><td><p>£000s</p></td></tr><tr><td><p>Driver Fee Paying Enquiries</p></td><td><p>4,597</p></td></tr><tr><td><p>Vehicle Fee Paying Enquiries</p></td><td><p>350</p></td></tr><tr><td><p>Electronic Data Link Fee Paying Enquiries</p></td><td><p>15,951</p></td></tr><tr><td><p>Receipts / Sale Vehicles including Bulk Data</p></td><td><p>1,920</p></td></tr><tr><td><p><strong>Total</strong></p></td><td><p><strong>22,818</strong></p></td></tr></tbody></table><p> </p><p> </p> answering member constituency Hereford and South Herefordshire answering member printed Jesse Norman question first answered 12/11/2018 17:59:22 answering member 3991 label Biography information for Jesse Norman
tabling member	4488 label Biography information for Martyn Day

1002678

registered interest
date	06/11/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, if he will publish the advice used to inform his Department on the requirements that (a) the decision to prescribe medicinal cannabis products must be made by a specialist doctor and (b) medicinal cannabis products may only be prescribed when the patient has an unmet special clinical need that cannot be met by other treatments.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	188750
answer	answer is ministerial correction date of answer 12/11/2018 answer text <p>The prescription of these products by doctors on the Specialist Register of the General Medical Council (GMC) and only where there is an unmet clinical need follows the principles used by the Interim Expert Panel on cannabis-based products for medicinal use. This approach was agreed by senior clinicians on the Expert Panel, Chaired by Dr Michael McBride, Chief Medical Officer for Northern Ireland. This approach was subsequently supported by the Advisory Council on the Misuse of Drugs (ACMD) in their advice to the Home Secretary on rescheduling cannabis. The ACMD advice has been published and is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products" target="_blank">https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products</a></p><p>Any unlicensed medicines, including cannabis-based products for medicinal use, will be supplied under long-standing arrangements for the supply of what are known, in healthcare settings, as ‘specials’. This process is underpinned by the Human Medicines Act and, outside of clinical trials, only allows these unlicensed medicines to be prescribed where there is an unmet clinical need. This restriction is in place because unlicensed medicines have not been through the same quality, safety and efficacy tests as licenced medicines.</p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 12/11/2018 17:05:51 answering member 1561 label Biography information for Mr Nick Hurd
tabling member	1439 label Biography information for Norman Lamb